WO2014021705A1 - Hypoxia inducible factor (hif) activity reporter cell line - Google Patents

Hypoxia inducible factor (hif) activity reporter cell line Download PDF

Info

Publication number
WO2014021705A1
WO2014021705A1 PCT/MY2013/000013 MY2013000013W WO2014021705A1 WO 2014021705 A1 WO2014021705 A1 WO 2014021705A1 MY 2013000013 W MY2013000013 W MY 2013000013W WO 2014021705 A1 WO2014021705 A1 WO 2014021705A1
Authority
WO
WIPO (PCT)
Prior art keywords
cell
hif
gene
cells
hypoxia
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/MY2013/000013
Other languages
English (en)
French (fr)
Inventor
Norazizah SHAFEE
Eric J. Stanbridge
Khatijah YUSOFF
Sien-Yei LIEW
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Universiti Putra Malaysia (UPM)
Original Assignee
Universiti Putra Malaysia (UPM)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Universiti Putra Malaysia (UPM) filed Critical Universiti Putra Malaysia (UPM)
Priority to EP13713255.1A priority Critical patent/EP2880177B1/en
Priority to US14/415,064 priority patent/US9995730B2/en
Priority to IN205DEN2015 priority patent/IN2015DN00205A/en
Priority to CN201380040870.5A priority patent/CN104662164A/zh
Priority to JP2015525393A priority patent/JP6309520B2/ja
Publication of WO2014021705A1 publication Critical patent/WO2014021705A1/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/66—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving luciferase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5023—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on expression patterns
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475—Assays involving growth factors
    • G01N2333/505—Erythropoietin [EPO]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/70—Mechanisms involved in disease identification
    • G01N2800/7038—Hypoxia

Definitions

  • CAT chloramphenicol acetyltransferase
  • Similar markers are known to work for vertebrate cell lines.
  • Most preferred in the context of the present invention is the use of a luciferase, most preferably wherein the reporter gene is a firefly luciferase.
  • the present invention relates to a gene construct comprising the exact 4 times the sequence of the human EPO HRE upstream of a TATA-box and the reporter gene.
  • Figure 7 Clone 3 cells displayed similar morphology to the parental Saos-2 cells following cultures in DMEM media with 10% FBS in a humidified C02 incubator at 37°C.
  • Figure 8 Different cells numbers gave the similar fold difference in bioluminescense intensity following hypoxia induction.
  • each well was topped up to 100 ⁇ with DMEM supplemented with G 418 and 10% FBS.
  • DMEM fetal calf serum
  • One hundred microliters of the same media was pipetted into the remaining 9 rows of empty wells.
  • Cell suspension from the first well 100 ⁇ was then transferred into the adjacent well and the mixture was pipetted up and down.
  • the same volume of cell suspension was then transferred from this well to the next. This process was repeated to obtain a two-fold serial dilution of the cell suspension. All of the cell suspension from the last well (200 ⁇ ) was diluted in 10 ml of conditioned DMEM supplemented with G 418 and 10% FBS. The mixture was then inverted up and down to ensure even distribution of cells.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Analytical Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
PCT/MY2013/000013 2012-08-02 2013-01-29 Hypoxia inducible factor (hif) activity reporter cell line Ceased WO2014021705A1 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
EP13713255.1A EP2880177B1 (en) 2012-08-02 2013-01-29 Hypoxia inducible factor (hif) activity reporter cell line
US14/415,064 US9995730B2 (en) 2012-08-02 2013-01-29 Hypoxia Inducible Factor (HIF) Activity Reporter Cell Line
IN205DEN2015 IN2015DN00205A (https=) 2012-08-02 2013-01-29
CN201380040870.5A CN104662164A (zh) 2012-08-02 2013-01-29 缺氧诱导因子(hif)活性报告细胞系
JP2015525393A JP6309520B2 (ja) 2012-08-02 2013-01-29 低酸素誘導因子（ｈｉｆ）活性レポーター細胞株

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
MYPI2012003492 2012-08-02
MYPI2012003492A MY172311A (en) 2012-08-02 2012-08-02 Hypoxia inducible factor (hif) activity reporter cell line

Publications (1)

Publication Number Publication Date
WO2014021705A1 true WO2014021705A1 (en) 2014-02-06

Family

ID=48040394

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/MY2013/000013 Ceased WO2014021705A1 (en) 2012-08-02 2013-01-29 Hypoxia inducible factor (hif) activity reporter cell line

Country Status (7)

Country Link
US (1) US9995730B2 (https=)
EP (1) EP2880177B1 (https=)
JP (1) JP6309520B2 (https=)
CN (1) CN104662164A (https=)
IN (1) IN2015DN00205A (https=)
MY (1) MY172311A (https=)
WO (1) WO2014021705A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018021653A1 (ko) * 2016-07-26 2018-02-01 울산대학교 산학협력단 Il-7 발현 리포터 세포주 및 이를 이용한 면역결핍 질환 치료제 스크리닝 방법

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2021240417A1 (en) * 2020-03-26 2022-10-20 AskBio Inc. Forskolin-inducible promoters and hypoxia-inducible promoters

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050037390A1 (en) * 2003-06-04 2005-02-17 Irm Llc, A Delaware Limited Liability Company Methods and compositions for modulating erythropoietin expression

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5834306A (en) * 1994-12-23 1998-11-10 Sri International Tissue specific hypoxia regulated therapeutic constructs

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050037390A1 (en) * 2003-06-04 2005-02-17 Irm Llc, A Delaware Limited Liability Company Methods and compositions for modulating erythropoietin expression

Non-Patent Citations (15)

* Cited by examiner, † Cited by third party
Title
DUYNDAM MC; VAN BERKEL MP; DORSMAN JC; ROCKX DA; PINEDO HM; BOVEN E: "Cisplatin and doxorubicin repress Vascular Endothelial Growth Factor expression and differentially down- regulate Hypoxia-inducible Factor I activity in human ovarian cancer cells", BIOCHEM PHARMACOL., vol. 74, 2007, pages 191 - 201
EK ET; DASS CR; CHOONG PF: "Commonly used mouse models of osteosarcoma", CRIT REV ONCOL HEMATOL, vol. 60, 2006, pages 1 - 8
FOGH J; FOGH JM; ORFEO T: "One hundred and twenty-seven cultured human tumor cell lines producing tumors in nude mice", J NATL CANCER INST, vol. 59, 1977, pages 221 - 6
JI DB; ZHU HB; YE J; LI CL: "Establishment of a cell-based sssay to screen regulators of the hypoxia-Inducible factor-1-dependent vascular endothelial growth factor promoter", BIOL PHARM BULL, vol. 31, 2008, pages 2255 - 2259
KALUZ S ET AL: "Rational design of minimal hypoxia-inducible enhancers", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, ACADEMIC PRESS INC. ORLANDO, FL, US, vol. 370, no. 4, 13 June 2008 (2008-06-13), pages 613 - 618, XP022654744, ISSN: 0006-291X, [retrieved on 20080408], DOI: 10.1016/J.BBRC.2008.03.147 *
KALUZ, S.; M. KALUZOVA; E. J. STANBRIDGE: "The role of extracellular signal regulated protein kinase in transcriptional regulation of the hypoxia marker carbonic anhydrase IX", J CELL BIOCHEM, vol. 97, 2006, pages 207 - 16
KEITH B; SIMON MC: "Hypoxia-inducible factors, stem cells, and cancer", CELL, vol. 29, 2007, pages 465 - 72
RANKIN EB; WU C; KHATRI R; WILSON TL; ANDERSEN R; ARALDI E; RANKIN AL; YUAN J; KUO CJ; SCHIPANI E: "The HIF Signaling Pathway in Osteoblasts Directly Modulates Erythropoiesis through the Production ofEPO", CELL, vol. 149, 2012, pages 63 - 74
S. M. WOOD: "Selection and Analysis of a Mutant Cell Line Defective in the Hypoxia-inducible Factor-1 alpha -Subunit (HIF-1alpha ). CHARACTERIZATION OF HIF-1alpha -DEPENDENT AND -INDEPENDENT HYPOXIA-INDUCIBLE GENE EXPRESSION", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 273, no. 14, 3 April 1998 (1998-04-03), pages 8360 - 8368, XP055063962, ISSN: 0021-9258, DOI: 10.1074/jbc.273.14.8360 *
SHIBATA T ET AL: "Enhancement of gene expression under hypoxic conditions using fragments of the human vascular endothelial growth factor and the erythropoietin genes", INTERNATIONAL JOURNAL OF RADIATION: ONCOLOGY BIOLOGY PHYSICS, PERGAMON PRESS, USA, vol. 42, no. 4, 1 November 1998 (1998-11-01), pages 913 - 916, XP002975914, ISSN: 0360-3016, DOI: 10.1016/S0360-3016(98)00298-3 *
SIEN-YEI LIEW ET AL: "Hypoxia affects cellular responses to plant extracts", JOURNAL OF ETHNOPHARMACOLOGY, vol. 144, no. 2, 1 November 2012 (2012-11-01), pages 453 - 456, XP055063967, ISSN: 0378-8741, DOI: 10.1016/j.jep.2012.09.024 *
TANAKA T; KOJIMA I; OHSE T; INAGI R; MIYATA T; INGELFINGER JR; FUJITA T; NANGAKU M: "Hypoxia-inducible factor modulates tubular cell survival in cisplatin nephrotoxicity", AM J PHYSIOL RENAL PHYSIOL., vol. 289, 2005, pages F1123 - 33
WOLDEMICHAEL GM; VASSELLI JR; GARDELLA RS; MCKEE TC; LINEHAN WM; MCMAHON JB: "Development of a cell-based reporter assay for screening of inhibitors of hypoxia-inducible factor 2-induced gene expression", J BIOMOL SCREEN, vol. 11, 2006, pages 678
ZHENG K Y Z ET AL: "The expression of erythropoietin triggered by Danggui Buxue Tang, a Chinese herbal decoction prepared from Radix Astragali and Radix Angelicae Sinensis, is mediated by the hypoxia-inducible factor in cultured HEK293T cells", JOURNAL OF ETHNOPHARMACOLOGY, ELSEVIER SCIENTIFIC PUBLISHERS LTD, IE, vol. 132, no. 1, 28 October 2010 (2010-10-28), pages 259 - 267, XP027417957, ISSN: 0378-8741, [retrieved on 20100817] *
ZHOU W; DOSEY TL; BIECHELE T; MOON RT; HORWITZ MS; RUOHOLA-BAKER H: "Assessment of hypoxia inducible factor levels in cancer cell lines upon hypoxic induction using a novel reporter construct", PLOS ONE, vol. 6, 2011, pages E27460

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018021653A1 (ko) * 2016-07-26 2018-02-01 울산대학교 산학협력단 Il-7 발현 리포터 세포주 및 이를 이용한 면역결핍 질환 치료제 스크리닝 방법

Also Published As

Publication number Publication date
MY172311A (en) 2019-11-21
US20150168376A1 (en) 2015-06-18
EP2880177B1 (en) 2017-07-19
JP6309520B2 (ja) 2018-04-11
IN2015DN00205A (https=) 2015-06-12
CN104662164A (zh) 2015-05-27
JP2015524272A (ja) 2015-08-24
EP2880177A1 (en) 2015-06-10
US9995730B2 (en) 2018-06-12

Similar Documents

Publication Publication Date Title
Zhang et al. STAT3 cooperates with Twist to mediate epithelial-mesenchymal transition in human hepatocellular carcinoma cells
Wood et al. Microcephalin/MCPH1 associates with the Condensin II complex to function in homologous recombination repair
Candeias et al. Cancer‐specific mutations in p53 induce the translation of Δ160p53 promoting tumorigenesis
Sidor et al. Mask family proteins ANKHD1 and ANKRD17 regulate YAP nuclear import and stability
Kataria et al. C-terminal HSP90 inhibitors block the HIF-1 hypoxic response by degrading HIF-1α through the oxygen-dependent degradation pathway
Lee et al. Twist1 is essential in maintaining mesenchymal state and tumor-initiating properties in synovial sarcoma
US20110143960A1 (en) 3d-models for high-throughput screening drug discovery and development
US20090280111A1 (en) Isolation of the Mitotic Spindle Matrix and its Methods of Use
Lin et al. SH3GL3 functions as a potent tumor suppressor in lung cancer in a SH3 domain dependent manner
Zhong et al. The essential role of Giα2 in prostate cancer cell migration
Borisova et al. Protein translation rate determines neocortical neuron fate
US20160068861A1 (en) Method for detecting protein stability and uses thereof
Ivanova et al. A novel mechanism of E2F1 regulation via nucleocytoplasmic shuttling: determinants of nuclear import and export
Li et al. Circ8199 encodes a protein that inhibits the activity of OGT by JAK2-STAT3 pathway in esophageal squamous cell carcinoma
US9995730B2 (en) Hypoxia Inducible Factor (HIF) Activity Reporter Cell Line
Duex et al. Recruitment of Uev1B to Hrs-containing endosomes and its effect on endosomal trafficking
Gonzaga-Saavedra et al. Nucleation-dependent propagation of Polycomb modifications emerges during the Drosophila maternal to zygotic transition
JP2019089726A (ja) がん遺伝子産物ｙａｐ１／ｔａｚ機能調節剤
Vos et al. RASSF family proteins and Ras transformation
Lin et al. Interaction between Nm23 and the tumor suppressor VHL
US8574837B2 (en) System for screening agonists/antagonists of cellular signaling pathways
US20070072186A1 (en) Methods and agents for screening for compounds capable of modulating her2 expression
US20030211523A1 (en) Two-hybrid double screening system and method
Hevér et al. Ets2 is not required for Ras or Neu/ErbB-2 mediated cellular transformation in vitro
Schott From lost adhesion to tumor spreading: the upregulation of IGF2BP1 controls a targetable mesenchymal shift in ovarian cancer

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 13713255

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 14415064

Country of ref document: US

REEP Request for entry into the european phase

Ref document number: 2013713255

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2013713255

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2015525393

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE